Overview

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
1994-07-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Sandoz
Treatments:
Nadolol
Criteria
Inclusion Criteria:

- No clinically significant abnormal finding on physical exam, medical history, or
clinical laboratory results on screening.

Exclusion Criteria:

- Positive test results for HIV or hepatitis B or C.

- Treatment for drug or alcohol dependence.